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Abstract
Introduction The objective of our study was to identify the
significance of the subtypes of dendritic cell (DC), specifically
myeloid DCs (mDCs) and plasmacytoid DCs (pDCs), in
rheumatoid arthritis (RA) pathogenesis through their longitudinal
follow-up in patients receiving infliximab.
Methods Circulating mDC and pDC levels were evaluated by
flow cytometry in RA patients (n = 61) and healthy volunteers (n
= 30). In RA patients, these levels were measured before and
during infliximab therapy. Their counts were correlated to RA
disease activity markers and anti-nuclear antibody occurrence.
IFNα production was measured by ELISA in serum of RA
patients and, in vitro, in supernatant of peripheral blood
mononuclear cells stimulated by influenza virus in the presence
or absence of infliximab. Statistical evaluations were based on
Mann–Whitney tests or Wilcoxon's signed-rank tests.
Results RA patients with active disease were characterized by
a baseline decrease in both circulating pDCs and mDCs.
Disease activity markers inversely correlated only with mDC
level. This level increased in RA patients responsive to infliximab
therapy, to reach the level observed in controls. Conversely, anti-
nuclear antibody appearance during infliximab therapy
correlated inversely with pDC level and was associated with
increased serum IFNα level and circulating plasma cells number.
In vitro studies revealed that infliximab kept pDCs in an IFNα
secreting state upon viral stimulation allowing differentiation of
B cells into anti-nuclear antibody-secreting plasma cells.
Conclusions This study reveals two distinct roles for pDC and
mDC in RA. Circulating mDCs mainly contribute to RA activity,
whereas pDCs seem to be involved in appearance of anti-
nuclear antibodies under infliximab therapy through the ability of
this drug to keep pDCs in an IFNα secreting state.
Introduction
Dendritic cells (DCs) represent a critical link between innate
and adaptive immune systems. Two DC subsets, myeloid den-
dritic cells (mDCs) and plasmacytoid dendritic cells (pDCs),
have been identified in humans. These DC subsets recognize
different microbial pathogens through specific receptors,
which in turn induce different types of innate and adaptive
immune responses [1]. Abnormalities of DC homeostasis have
been involved in the pathophysiology of various human dis-
eases, including autoimmune diseases [2]. In systemic lupus
erythematosus (SLE), an autoimmune disease characterized
by the presence of an autoimmune reaction against nuclear
components, pDCs secrete large amounts of IFNα. This
secretion promotes the differentiation of monocytes into
mDCs. These mDCs capture circulating nucleic acid-contain-
ing bodies and activate autoreactive T cells and B cells, lead-
ing to the increased production of autoantibodies by plasma
cells [3,4].
ANA: anti-nuclear antibody; DAS28: Disease Activity Score in 28 joints; DC: dendritic cell; ELISA: enzyme-linked immunosorbent assay; EULAR: 
European league against rheumatism; FCS: fetal calf serum; IFN: interferon; IL: interleukin; mDC: myeloid dendritic cell; PBMC: peripheral blood 
mononuclear cell; PBS: phosphate-buffered saline; pDC: plasmacytoid dendritic cell; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; 
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Rheumatoid arthritis (RA) is a common inflammatory disease,
yet its pathogenesis remains incompletely understood. It is
probable that DCs could play a key role in its pathogenesis as
they have been reported to infiltrate the synovium in RA
patients [5,6]. These synovial DCs are more mature than DCs
from peripheral blood: they express various activation markers,
secrete large amounts of various cytokines (IL-12, TNFα, IL-6),
and are able to activate autologous T lymphocytes as well as
B lymphocytes [7-9]. Trying to dissect and decipher the exact
roles of mDC and pDC subsets in this disease, however,
remains difficult because both subsets are present in RA syn-
ovial fluid and infiltrate synovial tissues [10,11].
Anti-TNFα therapies have improved the prognosis of RA,
although these agents may induce a number of adverse effects
including autoimmunity. Anti-nuclear antibodies (ANAs)
develop in 30 to 60% of the patients given anti-TNFα regi-
mens [12-14] and, occasionally, clinical lupus develops during
the course of therapy [15,16]. The mechanism responsible is
still unclear. The TNF/TNF-receptor system appears to play an
important role in SLE pathogenesis, as is exemplified by TNFα-
induced amelioration of murine lupus nephritis [17] and an
increased soluble TNF-receptor correlation with disease activ-
ity [18]. These data suggest a role of anti-TNFα in exacerba-
tion or induction of lupus-type autoimmunity and, therefore,
could explain some events occurring in patients treated by
TNFα blockers. Despite these observations, a recent study
has suggested that SLE can be treated with infliximab,
although autoantibodies to double-stranded DNA and cardiol-
ipin were increased [19].
To understand the implication of DC subsets in RA immunopa-
thology, we examined peripheral pDC and mDC numbers in
patients suffering from active RA and the evolution of these
numbers during the course of infliximab treatment. Our study
demonstrates that RA activity correlates with fluctuations in
mDC numbers and reveals a possible role for the pDCs,
through their sustained IFNα production, in the ANA produc-
tion induced by infliximab.
Materials and methods
Study population
Sixty-one patients with active RA (Disease Activity Score in 28
joints (DAS28) >5.1), who fulfilled the revised classification
criteria of the American College of Rheumatology for RA [20],
were evaluated before and after infliximab therapy. Table 1
summarizes the characteristics of these patients.
Infliximab (Shering-Plough, Levallois-Perret, France) was given
at a dose of 3 mg/kg intravenously at weeks 0, 2 and 6 and
then every 8 weeks in combination with stable doses of meth-
otrexate 7.5 to 15 mg/week orally or intramuscularly. Only
patients on stable prednisone doses ≤ 10 mg/day and nons-
teroidal anti-inflammatory drug treatment were included.
According to EULAR response criteria [21], a positive clinical
response to infliximab therapy was defined as a drop in the
DAS28 from baseline by >1.2 or as a DAS28 <3.2 at week
14.
In addition, 30 healthy blood donors were included in the
study. These donors were matched with patients for sex and
age. Synovial fluid was obtained from 11 patients suffering
from osteoarthritis.
The study was approved by the local Ethics Committee, and
all patients gave informed consent.
Enumeration of blood dendritic cell precursors and 
plasma cells by flow cytometry
Whole blood samples were analyzed on a FACSCalibur flow
cytometer (BD Biosciences, Pont-de-Claix, France) with 106
white blood cells acquired per analysis. DC subsets were
measured using a DC kit from BD Biosciences. Peripheral
blood mDC and pDC subsets were defined by the concomi-
tant lack of lineage markers, HLA-DR expression, and mutually
exclusive membrane expression of CD11c or CD123, respec-
tively. Absolute numbers of blood DC precursors were calcu-
lated as the percentage of white blood cells expressed per
milliliter of peripheral blood. Enumeration of blood DC was
evaluated as published elsewhere [22]. Plasma cells were
analyzed by gating on CD19+ cells and by calculating the per-
centage of CD20neg/CD38high cells.
Synovial fluid was obtained at the initial time point from
patients with RA (n = 9) and from patients with osteoarthritis
(n = 11), with knee effusions. This synovial fluid was diluted
appropriately with PBS in order to avoid clot formation. Syno-
vial mDC and pDC subsets were defined by the concomitant
lack of lineage markers (CD3-, CD14-, CD16-, CD56-, CD8-
and CD19-), HLA-DR expression, and mutually exclusive mem-
brane expression of CD11c or CD123, respectively. Results
were expressed as the percentage of mDCs or pDCs among
Table 1
Baseline characteristics of the study patients
Characteristic Baseline value
Age (years) 55 (24 to 82)
Sex ratio (female:male) 7:3
Disease status
Disease duration (years) 14 (2 to 34)
Rheumatoid factor positivity (%) 76
Anti-cyclic citrullinated peptide positivity (%) 59
Disease Activity Score in 28 joints score 6.14 ± 1.38
C-reactive protein (mg/l) 36.2 ± 30.5
Data presented as mean (range) or mean ± standard deviation 
unless otherwise indicated.Available online http://arthritis-research.com/content/11/3/R100
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cells without the following lineage markers: CD3, CD14,
CD16, CD56, CD8 and CD19.
IFNα quantification
Serum samples were collected and were stored at -80°C.
IFNα levels were quantified with a human IFNα ELISA kit (Bio-
Source International, Camarillo, CA, USA), according to the
manufacturer's instructions. The detection limit of this IFNα
ELISA is 25 pg/ml. This assay has been used previously by
others groups for measurement of IFNα in the serum [3,23].
Preparation of cell culture
Peripheral blood mononuclear cells (PBMCs) of adult donors
were isolated using Ficoll-Paque Plus (Amersham Bio-
sciences, Saclay, France) gradient centrifugation. PBMCs (1
× 106 cells/well) were cultured in RPMI supplemented with
10% FCS, and were stimulated in vitro with live influenza virus
(104 particles; Charles River Laboratories, Wilmington, MA,
USA) with or without TNFα (10 μg/ml; R&D Systems, Lille,
France) or TNFα blockers (Infliximab 20 μg/ml; Shering-
Plough) in 96-well U-bottom plates. The infliximab dose used
in vitro is comparable with the infliximab serum concentration
found in vivo during the first weeks after the infusion [24]. After
24 hours incubation, supernatants were collected. Depending
on the conditions, cells were further incubated in fresh RPMI
with live influenza virus (104 particles; Charles River Laborato-
ries). After 24 hours, the supernatants were again collected for
IFNα quantification by ELISA.
Plasma cell generation and antibody production
PBMCs were isolated by Ficoll-Paque Plus (Amersham Bio-
sciences, Saclay, France) gradient centrifugation – from RA
patients treated by infliximab who had developed significant
ANA titers, from healthy donors and from SLE patients.
PBMCs (1 × 106/well) were then cultured with 104 influenza
virus particles (Charles Rivers, Wilmington, MA, USA) with or
without TNFα (10 μg/ml; R&D Systems) or TNFα blockers (Inf-
liximab 20 μg/ml; Schering-Plough, Levallois-Perret, France) in
a 48-well plate in 10% FCS RPMI supplemented with rhIL-2
(50 U/ml; R&D Systems, Lille, France). At day 15, superna-
tants were collected and tested for ANAs. The resulting B
cells were analyzed using flow cytometry after gating on
CD19+ cells and by calculating the percentage of CD20low/
CD38high cells.
Statistical analysis
Statistical analysis was performed using the GraphPad InStat
software (version 3.0a for Macintosh; GraphPad Software,
San Diego, CA, USA). Mann–Whitney tests were used for
mean comparisons between groups. Wilcoxon's signed-rank
test was used for the analyses of matched pairs. Correlation
between DCs and activity markers were assessed using linear
regression, given with the r2 correlation coefficient. P < 0.05
was considered statistically significant.
Results
Blood dendritic cell subsets in RA and their correlation 
with disease activity
To better delineate the involvement of known DC subsets in
RA pathogenesis, we compared the number of circulating
CD11c+HLA-DR+CD123-  mDCs and CD11c-HLA-
DR+CD123+ pDCs in peripheral blood from 61 active RA
patients (free of TNFα-blocker treatment) and from 30 healthy
volunteers. Interestingly, RA peripheral blood was character-
ized by a decreased number of both pDC and mDC subsets
(mean ± standard deviation): mDC count = 10,214 ± 7,576
cells/ml in the RA group versus 16,228 ± 4,057 cells/ml in the
healthy control group (P = 0.0002), and pDC count = 6,098
± 4,710 cells/ml in the RA group versus 10,313 ± 4,201 cells/
ml in the healthy control group (P < 0.0001) (Figure 1). We
concluded that RA patients are characterized by a quantitative
deficit in their peripheral circulating DCs.
We then looked for a correlation between absolute counts of
blood DCs and the clinical status or laboratory tests known to
reflect disease activity (DAS28, Health Assessment Question-
naire score, and C-reactive protein level). In RA patients, mDC
counts were inversely correlated with each of these markers (P
< 0.05, r2 = 0.07, P < 0.02, r2 = 0.11 and P < 0.05, r2 = 0.11,
respectively, for DAS28, Health Assessment Questionnaire
score and C-reactive protein level). We did not find any statis-
tical correlation between the pDC counts and DAS28, Health
Figure 1
Circulating dendritic cell subset levels in patients with active rheuma- toid arthritis and in healthy volunteers Circulating dendritic cell subset levels in patients with active rheuma-
toid arthritis and in healthy volunteers. Dendritic cell (DC) subsets were 
measured in the peripheral blood of patients with rheumatoid arthritis 
(RA) (n = 61) and in healthy subjects (n = 30). The mean numbers per 
milliliter of blood of CD11c+CD123-Lin-HLA-DR+ myeloid dendritic 
cells (mDCs) and CD11c-CD123+Lin-HLA-DR+ plasmacytoid dendritic 
cells (pDCs) are shown (mean ± standard deviation). *P < 0.0001 and 
**P < 0.001, Mann–Whitney U test.Arthritis Research & Therapy    Vol 11 No 3    Richez et al.
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Assessment Questionnaire score or C-reactive protein level
(Figure 2a,b,c).
The levels of both DC subsets are therefore decreased in the
blood of RA patients with active disease, but only mDCs cor-
relate inversely with disease activity – suggesting that this
mDC decrease could reflect a migration to inflamed tissues.
Accordingly, we found a higher percentage of mDCs in syno-
vial fluid from active RA patients compared with that from
patients with osteoarthritis (percentage ± standard deviation:
mDC = 52.5 ± 13.7% in the RA group vs. 17.4 ± 18.3% in
the osteoarthritis control group; P = 0.0005). In contrast, the
percentage of pDCs in synovial fluid was not different
between the RA and the osteoarthritis groups (percentage ±
standard deviation: pDC = 8.4 ± 10.9% in the RA group vs. 2
± 3.9% in the osteoarthritis control group, P = 0.1119) (Figure
2d). The preferential migration of mDCs to inflamed joints was
also suggested by the increase of the mDC:pDC ratio in syn-
ovial fluid compared with that found in peripheral blood
(median, 3.8:1; P < 0.01, Wilcoxon matched-pairs test) (Fig-
ure 2e).
Evolution of dendritic cell subset counts in infliximab-
treated RA patients and correlation with the treatment 
response
Our initial results suggest that mDCs migrate from the blood
to the inflamed synovial compartment. If this is the case, it
seemed likely that effective therapy might block this migration
and increase the blood mDC level.
Responders to the infliximab regimen (n = 46) were defined by
a DAS28 decrease >1.2 after 14 weeks of infliximab therapy,
whereas nonresponders (n = 13) were patients defined by a
DAS28 variation <1.2 at week 14. Responders showed a sub-
stantial increase in their numbers of circulating mDCs (mean
± standard deviation = 11,915 ± 8,630 cells/ml at day 0 vs.
15,868 ± 11,467 cells/ml at week 14, P < 0.05 using Wil-
coxon matched-pairs test) (Figure 3a), whereas the blood
pDC level did not change significantly (5,632 ± 3,035 cells/ml
at day 0 vs. 6,555 ± 4,656 cells/ml at week 14, P = 0.23) (Fig-
ure 3b). In contrast, nonresponders did not show statistically
significant changes in mDC and pDC counts, and some
patients even showing a decrease in both DC subsets during
the course of treatment (mean ± standard deviation: mDCs =
7,991 ± 4,275 cells/ml at day 0 vs. 8,386 ± 3,689 cells/ml at
week 14, P = 0.41; and pDCs= 5,542 ± 3,525 cells/ml at day
0 vs. 4,649 ± 2,032 cells/ml at week 14, P = 0.27) (Figure
3a,b). These data suggest the existence of a relationship
between the fluctuations of the mDCs present in the blood
and the variations of disease activity.
Plasmacytoid dendritic cell number and blood IFNα 
levels correlate with anti-nuclear antibody positivity in 
infliximab-treated RA patients
The development of ANA is one of the most common side
effects of TNFα-blocker therapies [25,26]. We therefore
looked for a correlation between ANA appearance and DC
count evolution in RA patients treated with infliximab.
The ANA levels were determined at the same time as the
peripheral DC levels. After 14 weeks of treatment, we sepa-
rated infliximab-treated patients into two groups: patients with
positive ANA (n = 30) and patients with negative ANA (n =
16). The ANA level was considered positive when the serum
dilution giving a positive signal in the indirect immunofluores-
cence on Hep-2 cells was above 1:250 and negative at the
beginning of the treatment, or if the dilution increment reached
at least three times the dilution observed at treatment onset.
All of the data were obtained on day 0 of treatment onset and
at week 14.
At week 14, the pDC levels were statistically lower in the ANA-
positive group when compared with the ANA-negative group
(mean ± standard deviation: circulating pDCs = 5,509 ±
3,161 cells/ml vs. 9,324 ± 5,834 cells/ml, P < 0.01) (Figure
4a). Although no statistically significant difference was found
in the mDC subset between the two groups (data not shown),
the decrease of peripheral pDC counts correlated with the
increase of ANA titers (P = 0.02, r2 = 0.15) (Figure 4b).
Because IFNα and pDCs have been implicated in autoanti-
body production in SLE pathogenesis [3], we measured the
IFNα level in the blood of both ANA-positive and ANA-nega-
tive RA patients treated by infliximab. We found that RA
patients developing ANA were characterized by higher levels
of IFNα (310 pg/ml vs. 47 pg/ml, P < 0.01), suggesting that
infliximab influences pDC homeostasis and promotes the pro-
duction of ANAs through the secretion of IFNα (Figure 4c).
Anti-TNFα antibody infliximab keeps plasmacytoid 
dendritic cells in an IFNα secreting state
The presence of higher amounts of IFNα in RA ANA-positive
patients prompted us to analyze the effects of infliximab on
pDCs' ability to secrete IFNα in vitro. PBMCs from control
donors were exposed to influenza virus alone or in the pres-
ence of infliximab. Influenza virus was used as a well-known
strong pDC-IFNα inducer. We did not find any increase in cel-
lular apoptosis of the cells in any of the conditions tested (data
not shown). In both conditions (virus alone or virus + inflixi-
mab), we detected high levels of IFNα in the supernatant col-
lected after 24 hours culture, without any differences between
the two conditions (Figure 5). Repeat exposure of PMBCs to
influenza virus, however, was able to induce large IFNα pro-
duction only in the presence of infliximab. Furthermore,
PBMCs pretreated with TNFα were unable to secrete signifi-
cant amounts of IFNα. Although these studies were performedAvailable online http://arthritis-research.com/content/11/3/R100
Page 5 of 10
(page number not for citation purposes)
Figure 2
Correlation between circulating dendritic cell subsets and disease activity markers Correlation between circulating dendritic cell subsets and disease activity markers. Circulating plasmacytoid dendritic cell (pDC) and myeloid den-
dritic cell (mDC) counts (mean numbers/ml blood) from rheumatoid arthritis (RA) patients (n = 60) plotted against (a) Health Assessment Question-
naire (HAQ) score, (b) Disease Activity Score in 28 joints (DAS28), and (c) C-reactive protein (CRP) level. (d) The mDC level in synovial fluid (SF) 
of patients with active RA is significantly increased compared with that in osteoarthritis patients. Dendritic cell (DC) subsets were measured in the 
SF of patients with RA (n = 9) and in osteoarthritis patients (n = 11). The percentage of CD11c+CD123-HLADR+ mDCs and CD11c-
CD123+HLADR+ pDCs in Lin- cells (CD3-, CD14-, CD16-, CD56-, CD8-, CD19-) are shown (mean ± standard deviation). **P < 0.001, Mann–Whit-
ney U test. (e) The mDC:pDC ratio in SF from RA subjects is significantly increased compared with the ratio in matched peripheral blood (PB) sam-
ples. Squares and triangles indicate individual matched samples (n = 9). The ratio is calculated from the percentage of mDCs and pDCs in Lin- cells. 
***P < 0.01, Mann–Whitney U test.Arthritis Research & Therapy    Vol 11 No 3    Richez et al.
Page 6 of 10
(page number not for citation purposes)
with PBMCs, it is probable that pDCs were the major source
of IFNα given that they are the major IFNα-producing cells in
peripheral blood. These data strongly suggest that infliximab
maintains pDCs in an IFNα secreting state by quenching
TNFα.
Infliximab increases plasma cell generation and 
promotes in vitro anti-nuclear antibody secretion
Jego and colleagues showed that pDCs exposed to viral infec-
tion were able to activate the B-lymphocyte compartment and
to promote the generation of plasma cells and/or plasmablasts
in an IFNα-dependent and IL-6-dependent fashion [4]. To
delineate the consequences of the sustained IFNα secretion
induced by infliximab, we compared the proportion of circulat-
ing CD19+CD20-CD38+ plasma cells in RA ANA-positive
patients (n = 10) and RA ANA-negative patients (n = 10). RA
ANA-positive patients exhibited a significant increase (P <
0.001) of the proportion of circulating plasma cells compared
with RA ANA-negative patients (Figure 6a). The percentage of
plasma cells in RA ANA-positive patients was similar to that
observed in SLE patients.
We then tested, in vitro, whether infliximab effects plasma cell
generation from B lymphocytes. PBMCs were cultured with
influenza virus with or without infliximab. After 15 days, we
measured the proportion of CD19+CD20-CD38high+ plasma
cells. PBMCs cultured with influenza virus + infliximab were
characterized by a higher proportion of plasma cells. Interest-
ingly, concomitant addition of TNFα with virus stimulation
inhibited plasma cell generation (Figure 6b). To analyze the in
vitro effects of infliximab on ANA secretion, we repeated the
experiment with PBMCs from RA ANA-positive patients, SLE
patients and healthy control individuals. These PBMCs were
cultured for 15 days in the presence of influenza virus with or
without infliximab. After 15 days the secretion of ANA was
found only in supernatants from cells from RA ANA-positive
patients or SLE patients, and was further increased in the
presence of infliximab (Figure 6c).
Taken together, those results suggest that infliximab promotes
pDCs in an IFNα secreting state and allows for the differenti-
ation of B lymphocytes into ANA-secreting plasma cells.
Discussion
DCs are thought to play a key role in driving the immunopath-
ogenic response underlying chronic inflammatory arthritis. Var-
ious studies [9,27-29] have shown that both mDCs and pDCs
accumulate in synovial tissue and synovial fluid of RA patients.
The evolution of circulating peripheral blood DC counts under
TNFα blocker therapy has never been studied, however, but it
may provide important information on the implication of both
subsets in RA pathogenesis.
In the present study we show that RA patients are character-
ized by a significant decrease in circulating mDCs and pDCs,
consistent with previous results from Jongbloed and col-
leagues [11]. We, however, found that only mDC counts cor-
related inversely with RA activity as assessed by the Health
Assessment Questionnaire score, DAS28, and C-reactive
protein level, and that the percentage of mDC was increased
Figure 3
Evolution of circulating myeloid and plasmacytoid dendritic cell counts over 14-week treatment with infliximab Evolution of circulating myeloid and plasmacytoid dendritic cell counts over 14-week treatment with infliximab. Evolution of circulating myeloid den-
dritic cell (mDC) and plasmacytoid dendritic cell (pDC) counts over a 14-week period of treatment with infliximab in (a) responder patients (n = 46) 
and (b) nonresponder patients (n = 13). Squares indicate matched samples. *P < 0.05, using Wilcoxon matched-pairs test.Available online http://arthritis-research.com/content/11/3/R100
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in the inflamed synovial tissue. Moreover, in the presence of
effective infliximab therapy, circulating mDC counts increased
to reach levels observed in healthy volunteers. Our results sug-
gest that, among DCs, mDCs have a prominent role in clinical
disease manifestations in RA patients since their circulating
numbers correlate directly with disease activity, and treatment
with infliximab corrects mDC count abnormalities in infliximab-
responsive patients.
The lack of correlation between pDC counts and RA clinical
evolution was unexpected because pDCs are known to play a
central role in various inflammatory diseases, including psoria-
sis [30], Sjogren's syndrome [31] and SLE [3]. It is probable
that other unknown parameters may alter pDC homeostasis in
RA patients. Psoriasis [32-34] and SLE (or more frequently
the appearance of ANA) [12-16] have been described as an
adverse effect of TNFα-blocker therapy. In both diseases,
pDCs are implicated in pathogenesis through their ability to
produce high amounts of IFNα [3,30]. In the case of SLE, this
occurs through uptake of the immune complex on the pDC cell
surface and the subsequent internalization and delivery of the
self-DNA or self-RNA within the complex to intracellular TLR9
or TLR7, respectively [35-37]. In the case of psoriasis, the
endogenous antimicrobial peptide LL37 forms a complex with
self-DNA that is delivered to and retained within early endo-
cytic compartments of pDCs to trigger TLR9 and to induce
IFNα production [38]. Interestingly, a recent study has
reported an increased IFNα expression and more severe pso-
Figure 4
Plasmacytoid dendritic cell number, blood IFNα and anti-nuclear anti- body positivity in infliximab-treated rheumatoid arthritis patients Plasmacytoid dendritic cell number, blood IFNα and anti-nuclear anti-
body positivity in infliximab-treated rheumatoid arthritis patients. (a) Cir-
culating plasmacytoid dendritic cell (pDC) levels in rheumatoid arthritis 
(RA) patients after 14 weeks of infliximab therapy. pDC subsets were 
measured in the peripheral blood of patients, and two groups were indi-
vidualized: patients with positive anti-nuclear antibody (ANA) (ANApos, 
n = 30) and patients with negative ANA (ANAneg, n = 16). Mean ± 
standard deviation shown. *P < 0.01, Mann–Whitney U test. (b) Corre-
lation between ANA levels and pDC variations under infliximab therapy. 
ANA levels (1/dilution) and the pDC amount were measured on the 
same blood draw, before each infliximab infusion. (c) Detecting IFNα in 
serum of RA patients treated by infliximab and developing or not ANA. 
IFNα levels (pg/ml) were measured in peripheral blood of RA patients 
under infliximab therapy with ANA (n = 30) or without ANA (n = 16). *P 
< 0.001, Mann–Whitney U test.
Figure 5
Infliximab maintains plasmacytoid dendritic cells exposed to influenza  virus in an IFNα secreting state Infliximab maintains plasmacytoid dendritic cells exposed to influenza 
virus in an IFNα secreting state. Peripheral blood mononuclear cells 
from control donors were exposed to influenza virus alone (Flu) or to 
influenza virus in the presence of infliximab. After 24 hours of incuba-
tion, the supernatant was collected and IFNα levels were measured by 
ELISA. The cell pellets were then washed, resuspended in fresh 
medium, and exposed for an additional 24 hours to influenza virus. 
Supernatants were analyzed by ELISA. Data are expressed as the 
mean ± standard error of the mean of three independent experiments.Arthritis Research & Therapy    Vol 11 No 3    Richez et al.
Page 8 of 10
(page number not for citation purposes)
riatic skin lesions in patients treated with TNF blockers [34],
implicating IFNα in the pathogenesis of psoriasis.
As previously proposed by Palucka and colleagues in sys-
temic-onset juvenile idiopathic arthritis [39], we thought pDCs
may be preferentially involved in the ANA response frequently
found in RA patients – which increases under treatment.
Indeed, we found a direct correlation between ANA levels and
decreased pDC variation. Furthermore, serum IFNα was sig-
nificantly increased in patients developing ANAs. Several
studies [39-41] evaluating IFNα production in autoimmune
diseases have measured IFNα gene expression and IFN-
inducible gene expression instead of measuring serum IFNα
protein levels because of the limited sensitivity of the ELISA
assay. In our study, however, the serum level of IFNα induced
by influenza was high enough to be detected at the protein
level, allowing the same ELISA assay to be used for both in
vivo and in vitro measurement of IFNα. Our results suggest
that migration of pDCs – which are known to enter lymph
nodes when they produce IFNα [42] – occurs, leading to their
decreased numbers at the periphery in the ANA-positive
group. Moreover, this IFNα secretion from pDCs has been
previously described to induce plasma cell differentiation and,
therefore, autoantibody production [4]. Accordingly, in vivo,
Figure 6
Infliximab enhances plasma cell differentiation Infliximab enhances plasma cell differentiation. (a) Circulating plasma cell levels in rheumatoid arthritis (RA) patients treated by infliximab with anti-
nuclear antibody (ANA) (n = 10) or without ANA production (n = 10), in patients with active systemic lupus erythematosus (SLE) (n = 10), and in 
healthy volunteers (n = 10). Plasma cell levels were measured in peripheral blood. The mean number/milliliter of CD38+CD19+CD20- is shown 
(mean ± standard deviation). *P < 0.001, Mann–Whitney U test. (b) Peripheral blood mononuclear cells (PBMCs) from healthy donors were cul-
tured out in the presence of influenza virus (Flu) with or without infliximab or TNFα. After 10 days, we analyzed by flow cytometry the proportion of 
CD19+CD20-CD38high+ plasma cells. Data expressed as the mean ± standard error of the mean of three independent experiments. (c) PBMCs from 
healthy donors, from RA patients treated by infliximab and developing ANAs, and from SLE patients were cultured in the presence of influenza virus 
with or without the TNFα blocker, infliximab. After 15 days, ANA titers were measured in the supernatants. Data expressed as mean ± standard error 
of the mean of three independent experiments.Available online http://arthritis-research.com/content/11/3/R100
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we found increased plasma cell generation in RA patients
developing ANAs during infliximab therapy.
IFNα-secreting pDCs have been described as being immature
or precursor DCs [43]. TNFα is known to differentiate imma-
ture DCs into a more mature stage [44] and to inhibit IFNα
induced by viruses [45]. TNFα-mediated maturation of pDCs
could block the IFNα-producing ability of pDCs. Conversely,
pDCs stimulated by viruses secrete high amount of IFNα and
TNFα that could act in an autocrine loop to control IFNα
secretion through pDC maturation.
We confirm that TNFα blocks the ability of pDCs to secrete
IFNα upon viral stimulation, and that the TNFα antagonist, inf-
liximab, keeps pDCs in an IFNα secreting state. This result and
our in vivo data described above are consistent with a previ-
ous report showing that, in vitro, TNFα blockers inhibit virus-
induced maturation of pDCs and increase IFNα secretion
[39]. The authors suggested that this inhibition may explain the
increase of ANA production in patients treated with TNFα
blockers. We confirmed their findings by showing, in vitro and
in vivo, the ability of infliximab to increase IFNα secretion,
plasma cell differentiation and ANA generation. de Rycke and
colleagues, however, have previously described differences in
ANA induction between infliximab and etanercept in patients
suffering from spondylarthropathy [13]. It will therefore be
important to determine in future work whether other TNF
blockers (adalimumab and etanercept) have the same ability
as infliximab to maintain pDCs in an IFNα secreting state.
Conclusions
Although both subtypes of circulating DCs are reduced in
active RA patients' peripheral blood, only mDC levels corre-
lated with disease activity, suggesting a possible link to RA
pathogenesis. The exact role of pDCs in RA remains unclear,
but these cells seem likely to play an important role in lupus-
like complications of infliximab therapy as they do in lupus.
We confirmed that infliximab acts on the regulation of IFNα
system in vivo and in vitro, by enhancing plasma cell differen-
tiation, which is ultimately responsible for autoantibody secre-
tion. Our results emphasize the balance between IFNα and
TNFα in RA, and provide mechanistic insights into the possi-
ble roles of DC subsets in mediating the shift in autoimmune
disease manifestations by therapeutics that inhibit TNFα.
These findings may also be relevant in other autoimmune dis-
eases where the role of IFNα and TNFα has been suggested,
such as psoriasis [30,46].
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